Christopher Chiu

9.7k citations

32 papers · 3.0k · 2 hit papers · h-index 20

Impact in

Hematology top 0.5%
- Multiple Myeloma Research and Treatments
Oncology top 2%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research

Papers in

Oncology 17
- Peptidase Inhibition and Analysis 8
- CAR-T cell therapy research 5
Hematology 14
- Multiple Myeloma Research and Treatments 14

Co-authors: Douglas Hanahan (4 shared papers)Hiroaki Nozawa (2 shared papers)Tahamtan Ahmadi (5 shared papers)A. Kate Sasser (5 shared papers)Niels W.C.J. van de Donk (5 shared papers)Henk M. Lokhorst (4 shared papers)Sagar Lonial (3 shared papers)Tineke Casneuf (6 shared papers)
Journals: Hematological Oncology (3 papers)Clinical Pharmacology & Therapeutics (2 papers)Blood Advances (2 papers)Haematologica (2 papers)Proceedings of the National Academy of Sciences (2 papers)
Partner nations: United States Netherlands Spain

In The Last Decade

Christopher Chiu

32 papers receiving 2.9k citations

Christopher Chiu's Hit Papers

align trajectories log scale

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study 2021 · 212 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 The Lancet
2006 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Christopher Chiu

Since Specialization

Citations

This map shows the geographic impact of Christopher Chiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Chiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Chiu more than expected).

Fields of papers citing papers by Christopher Chiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Chiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Chiu. The network helps show where Christopher Chiu may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher Chiu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher Chiu Line = papers co-authored together Christopher Chiu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis Proceedings of the National Academy of Sciences ·Hiroaki Nozawa, Christopher Chiu, Douglas Hanahan Hit paper breakdown →	2006	728
2	Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma Blood ·Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jonathan L. Kaufman, Jainulabdeen J. Ifthikharuddin, Brendan M. Weiss, Amrita Krishnan, Suzanne Lentzsch, Raymond L. Comenzo, Jianping Wang, Kerri Nottage, Christopher Chiu, Nushmia Z. Khokhar, Tahamtan Ahmadi, Sagar Lonial	2017	317
3	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma Blood ·Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy Axel, Khaja Syed, Richard W.J. Groen, Mark van Duin, Pieter Sonneveld, Monique C. Minnema, Sonja Zweegman, Christopher Chiu, Andries C. Bloem, Tuna Mutis, Henk M. Lokhorst, A. Kate Sasser, Niels W.C.J. van de Donk	2016	275
4	Requirement for B Cell Linker Protein (BLNK) in B Cell Development Science ·Rajita Pappu, Alec M. Cheng, Bin Li, Qian Gong, Christopher Chiu, Nancy Griffin, J. Michael White, Barry P. Sleckman, Andrew C. Chan	1999	234
5	Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study The Lancet ·Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim Linton, Martine E.D. Chamuleau, David Lewis, Anna Sureda, David Cunningham, Roberto S Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Kuo-mei Chen, Tahamtan Ahmadi, Pieternella J. Lugtenburg Hit paper breakdown →	2021	212
6	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma Blood Advances ·Tineke Casneuf, Xu Steven Xu, Homer Adams, Amy Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser	2017	160
7	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study Leukemia ·Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Maria Krevvata, Christopher Chiu, Xiang Qin, Linda Okonkwo, Sonali Trivedi, Jon Ukropec, Ming Qi, Jesús F. San Miguel	2020	158
8	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Clinical Cancer Research ·Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof, Berris van Kessel, Jeroen F. van Velzen, Andries C. Bloem, Marloes E.C. Broekmans, Sonja Zweegman, Johan van Meerloo, René J.P. Musters, Pino J. Poddighe, Richard W.J. Groen, Christopher Chiu, Torben Plesner, Henk M. Lokhorst, A. Kate Sasser, Tuna Mutis, Niels W.C.J. van de Donk	2017	119
9	BLNK: molecular scaffolding through 'cis'-mediated organization of signaling proteins The EMBO Journal ·Christopher Chiu	2002	95
10	High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action Cytometry Part A ·Homer Adams, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Christopher Chiu, Greet Vanhoof, Saad Z. Usmani, Torben Plesner, Sagar Lonial, Inger S. Nijhof, Henk M. Lokhorst, Tuna Mutis, Niels W.C.J. van de Donk, A. Kate Sasser, Tineke Casneuf	2018	94
11	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR Clinical Lymphoma Myeloma & Leukemia ·María‐Victoria Mateos, Pieter Sonneveld, Vânia Hungria, Ajay K. Nooka, Jane Estell, Wolney Barreto, Paolo Corradini, Chang‐Ki Min, Eva Medvedova, Katja Weisel, Christopher Chiu, Jordan M. Schecter, Himal Amin, Xiang Qin, Jon Ukropec, Rachel Kobos, Andrew Spencer	2019	93
12	Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis Journal of Clinical Oncology ·Christopher Chiu, Hiroaki Nozawa, Douglas Hanahan	2010	81
13	CD4+ T Cell-Mediated Antigen-Specific Immunotherapy in a Mouse Model of Cervical Cancer Cancer Research ·Dylan Daniel, Christopher Chiu, Enrico Giraudo, Masahiro Inoue, Lee Mizzen, Nina Chu, Douglas Hanahan	2005	65
14	Prostate-specific targeting using PSA promoter-based lentiviral vectors Cancer Gene Therapy ·Duan Yu, Dalin Chen, Christopher Chiu, Babak Razmazma, Yen‐Hung Chow, Shen Pang	2001	58
15	A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) ·Jasvinder K. Atwal, Y. Chen, Christopher Chiu, Deborah L. Mortensen, William J. Meilandt, yongchun liu, Constanze Heise, Kwame Hoyte, Wilman Luk, Y. Lu, Ke Peng, Peng Wu, Lionel Rougé, Y. Zhang, Robert A. Lazarus, Kimberly Scearce‐Levie, W. Wang, Yueh-Chin Wu, Marc Tessier‐Lavigne, Ryan J. Watts	2013	45
16	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies Haematologica ·María‐Victoria Mateos, Andrew Spencer, Ajay K. Nooka, Luděk Pour, Katja Weisel, Michèle Cavo, Jacob P. Laubach, Gordon Cook, Shinsuke Iida, Lotfi Benboubker, Saad Z. Usmani, Sung‐Soo Yoon, Nizar J. Bahlis, Christopher Chiu, Jon Ukropec, Jordan M. Schecter, Xiang Qin, Lisa O’Rourke, Meletios Α. Dimopoulos	2019	43
17	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens Haematologica ·Anna Vidal‐Crespo, Alba Matas‐Céspedes, Vanina Rodríguez, Cédric Rossi, Juan García Valero, Neus Serrat, Alejandra Sanjuán-Pla, Pablo Menéndez, Gaël Roué, Armando López‐Guillermo, Eva Giné, Elı́as Campo, Dolors Colomer, Christine Bezombes, Jeroen Lammerts van Bueren, Christopher Chiu, Parul Doshi, Patricia Pérez‐Galán	2019	32
18	Dose properties of a laser accelerated electron beam and prospects for clinical application Medical Physics ·K. Kainz, Kenneth R. Hogstrom, John A. Antolak, Peter R. Almond, C. Bloch, Christopher Chiu, Mykhailo V. Fomyts’kyi, Frank Raischel, M. C. Downer, T. Tajima	2004	30
19	Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting Blood Advances ·Maissa Mhibik, Erika M. Gaglione, David Eik, John H. Herrick, J. Le, Inhye E. Ahn, Christopher Chiu, Monica Wielgos-Bonvallet, Ida H. Hiemstra, Esther C.W. Breij, Jenny Chen, Edward B. Reilly, Pearlie K. Epling‐Burnette, Edith Szafer-Glusman, Clare Sun, Adrian Wiestner	2023	27
20	Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas Clinical Pharmacology & Therapeutics ·Tommy Li, Ida H. Hiemstra, Christopher Chiu, Roberto S Oliveri, Brian Elliott, Dena DeMarco, Theodora W. Salcedo, Frederikke Lihme Egerod, Kate Sasser, Tahamtan Ahmadi, Manish Gupta	2022	25

About Christopher Chiu

Christopher Chiu is a scholar working on Oncology, Hematology, Molecular Biology, Genetics and Immunology, having authored 32 papers that have together received 3.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (14 papers), Peptidase Inhibition and Analysis (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Protein Degradation and Inhibitors (6 papers), CAR-T cell therapy research (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cancer therapeutics and mechanisms (3 papers). The work is most often cited by research in Hematology (1.1k citations), Oncology (1.6k citations), Immunology (1.1k citations), Genetics (358 citations) and Physiology (120 citations). Christopher Chiu has collaborated with scholars based in United States, Netherlands and Spain. Frequent co-authors include Douglas Hanahan, Hiroaki Nozawa, Tahamtan Ahmadi, A. Kate Sasser, Niels W.C.J. van de Donk, Henk M. Lokhorst, Sagar Lonial, Tineke Casneuf, Jonathan L. Kaufman and Tuna Mutis. Their work appears in journals such as Hematological Oncology, Clinical Pharmacology & Therapeutics, Blood Advances, Haematologica and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Christopher Chiu

Impact in

Papers in i

In The Last Decade

Christopher Chiu

Christopher Chiu's Hit Papers

Peers

Countries citing papers authored by Christopher Chiu

Fields of papers citing papers by Christopher Chiu

All Works

About Christopher Chiu

Explore authors with similar magnitude of impact

Papers in